BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Jeffrey Robert Ajer sold 18,467 shares of the company’s stock in a transaction that occurred on Tuesday, September 27th. The shares were sold at an average price of $95.61, for a total value of $1,765,629.87. Following the sale, the executive vice president now directly owns 41,342 shares of the company’s stock, valued at $3,952,708.62. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) opened at 92.52 on Monday. The firm’s market cap is $15.12 billion. BioMarin Pharmaceutical Inc. has a one year low of $62.12 and a one year high of $118.48. The company has a 50-day moving average price of $95.40 and a 200-day moving average price of $88.79.
BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, August 4th. The company reported ($2.61) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by $2.09. BioMarin Pharmaceutical had a negative return on equity of 11.99% and a negative net margin of 54.53%. The firm had revenue of $300.10 million for the quarter, compared to the consensus estimate of $278.75 million. During the same period in the previous year, the firm earned ($0.51) EPS. BioMarin Pharmaceutical’s revenue for the quarter was up 20.0% on a year-over-year basis. Equities analysts predict that BioMarin Pharmaceutical Inc. will post ($3.95) earnings per share for the current fiscal year.
Several analysts have commented on BMRN shares. JPMorgan Chase & Co. upped their price objective on BioMarin Pharmaceutical from $120.00 to $127.00 and gave the company an “overweight” rating in a research note on Friday, August 5th. Zacks Investment Research downgraded BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Thursday, July 14th. Piper Jaffray Cos. reaffirmed an “overweight” rating on shares of BioMarin Pharmaceutical in a research note on Friday, August 19th. Leerink Swann reaffirmed an “outperform” rating and set a $107.00 price objective on shares of BioMarin Pharmaceutical in a research note on Wednesday, June 22nd. Finally, Cowen and Company set a $150.00 price objective on BioMarin Pharmaceutical and gave the company a “buy” rating in a research note on Thursday, September 8th. Three equities research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $120.61.
A number of large investors have recently made changes to their positions in BMRN. Adage Capital Partners GP L.L.C. boosted its position in BioMarin Pharmaceutical by 316.3% in the first quarter. Adage Capital Partners GP L.L.C. now owns 1,052,900 shares of the company’s stock valued at $86,843,000 after buying an additional 800,000 shares in the last quarter. Candriam Luxembourg S.C.A. boosted its position in BioMarin Pharmaceutical by 18.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 247,100 shares of the company’s stock valued at $19,225,000 after buying an additional 38,628 shares in the last quarter. ING Groep NV bought a new position in BioMarin Pharmaceutical during the second quarter valued at about $57,357,000. Strs Ohio boosted its position in BioMarin Pharmaceutical by 50.7% in the second quarter. Strs Ohio now owns 491,556 shares of the company’s stock valued at $38,243,000 after buying an additional 165,472 shares in the last quarter. Finally, State Street Corp boosted its position in BioMarin Pharmaceutical by 5.6% in the first quarter. State Street Corp now owns 3,286,743 shares of the company’s stock valued at $271,074,000 after buying an additional 175,733 shares in the last quarter. 93.02% of the stock is currently owned by hedge funds and other institutional investors.
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc (BioMarin) develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).
Receive News & Ratings for BioMarin Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.